MENLO PARK, Calif.,
July 27, 2017 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, today announced that a panel of prominent dermatologists
will discuss BPX-01, a unique topical hydrophilic gel formulation
of minocycline at the 2017 AAD Summer Meeting tomorrow. BPX-01 is
an investigational drug for the treatment of acne and rosacea.
The discussion will take place during a three hour-long "Acne
and Rosacea Session" at 1 p.m.
Eastern, at the New York Hilton Midtown. Dermatologists involved in
the panel include Dr. James Del
Rosso, a board-certified dermatologist and researcher who is
a member of the BioPharmX Dermatology Medical Advisory Board; Dr.
Andrew Alexis, chairman of the
Department of Dermatology at Mount Sinai St. Luke's and Mount Sinai
West in New York City, and Dr.
Linda Stein Gold, director of
Dermatology Clinical Research at Henry Ford Health System in
Detroit.
Phase 2b data found BPX-01 reduced acne lesions by 59%,
delivered at least a two-grade reduction to clear or almost clear
in investigator global assessments for 25% of subjects and was
generally well tolerated, without any serious drug-related adverse
events, photosensitivity, staining or skin discoloration. A survey
of study participants found 86% would use BPX-01 again and 79% said
the drug was easy to use and apply.
"The dermatology community is excited about these promising
clinical results," said Hilary E.
Baldwin, MD, Clinical Associate Professor, Rutgers Robert
Wood Johnson Medical Center, Medical Director, Acne Treatment &
Research Center and Co-Chair of BioPharmX Medical Advisory Board,
"There has been little innovation in acne treatment for several
decades. BPX-01 could lead to significant change in the standard of
care."
The company is currently conducting an open-label phase 2
feasibility study for rosacea and continues making progress towards
the next phase in trials for acne vulgaris.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting up to 50 million
Americans. The disease can cause permanent scarring, low
self-esteem, depression and anxiety.
About BioPharmX® Corporation
BioPharmX
Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty
pharmaceutical company, which seeks to provide products through
proprietary platform technologies for prescription,
over-the-counter (OTC), and supplement applications in the health
and wellness markets, including dermatology and women's health. To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions, and
strategies, including, but not limited to, statements regarding the
safety and medical effects of BPX-01, the effect BPX-01 may have on
the treatment of acne, and the commencement of future trials of
BPX-01. These forward-looking statements may be identified by words
such as "plan," "expect," "anticipate," "believe" or similar
expressions that are intended to identify such forward-looking
statements.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the period
ended Jan. 31, 2017 and quarterly report on Form 10-Q for the
period ended April 30, 2017. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof, and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities law.
BioPharmX is a registered trademark of BioPharmX, Inc.
View original content with
multimedia:http://www.prnewswire.com/news-releases/summer-aad-panel-to-discuss-bpx-01-for-acne-and-rosacea-300495046.html
SOURCE BioPharmX Corporation